A Phase 1, Randomized, Open-Label, Single-Dose, 6-Period Crossover Study to Evaluate the Pharmacokinetics of BIIB091 Formulations and the Effect of Food in Healthy Participants
Latest Information Update: 25 Feb 2025
At a glance
- Drugs BIIB 091 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen
Most Recent Events
- 18 Feb 2025 Status changed from recruiting to completed.
- 24 Dec 2024 Planned End Date changed from 7 Dec 2024 to 10 Feb 2025.
- 24 Dec 2024 Planned primary completion date changed from 7 Dec 2024 to 10 Feb 2025.